Next-generation sequencing to guide cancer therapy
As a result of multiple technological and practical advances, high-throughput sequencing, known more commonly as “next-generation” sequencing (NGS), can now be incorporated into standard clinical practice. Whereas early protocols relied on samples that were harvested outside of typical clinical path...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517547/ |
| id |
pubmed-4517547 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-45175472015-07-29 Next-generation sequencing to guide cancer therapy Gagan, Jeffrey Van Allen, Eliezer M. Review As a result of multiple technological and practical advances, high-throughput sequencing, known more commonly as “next-generation” sequencing (NGS), can now be incorporated into standard clinical practice. Whereas early protocols relied on samples that were harvested outside of typical clinical pathology workflows, standard formalin-fixed, paraffin-embedded specimens can more regularly be used as starting materials for NGS. Furthermore, protocols for the analysis and interpretation of NGS data, as well as knowledge bases, are being amassed, allowing clinicians to act more easily on genomic information at the point of care for patients. In parallel, new therapies that target somatically mutated genes identified through clinical NGS are gaining US Food and Drug Administration (FDA) approval, and novel clinical trial designs are emerging in which genetic identifiers are given equal weight to histology. For clinical oncology providers, understanding the potential and the limitations of DNA sequencing will be crucial for providing genomically driven care in this era of precision medicine. BioMed Central 2015-07-29 /pmc/articles/PMC4517547/ /pubmed/26221189 http://dx.doi.org/10.1186/s13073-015-0203-x Text en © Gagan and Van Allen. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Gagan, Jeffrey Van Allen, Eliezer M. |
| spellingShingle |
Gagan, Jeffrey Van Allen, Eliezer M. Next-generation sequencing to guide cancer therapy |
| author_facet |
Gagan, Jeffrey Van Allen, Eliezer M. |
| author_sort |
Gagan, Jeffrey |
| title |
Next-generation sequencing to guide cancer therapy |
| title_short |
Next-generation sequencing to guide cancer therapy |
| title_full |
Next-generation sequencing to guide cancer therapy |
| title_fullStr |
Next-generation sequencing to guide cancer therapy |
| title_full_unstemmed |
Next-generation sequencing to guide cancer therapy |
| title_sort |
next-generation sequencing to guide cancer therapy |
| description |
As a result of multiple technological and practical advances, high-throughput sequencing, known more commonly as “next-generation” sequencing (NGS), can now be incorporated into standard clinical practice. Whereas early protocols relied on samples that were harvested outside of typical clinical pathology workflows, standard formalin-fixed, paraffin-embedded specimens can more regularly be used as starting materials for NGS. Furthermore, protocols for the analysis and interpretation of NGS data, as well as knowledge bases, are being amassed, allowing clinicians to act more easily on genomic information at the point of care for patients. In parallel, new therapies that target somatically mutated genes identified through clinical NGS are gaining US Food and Drug Administration (FDA) approval, and novel clinical trial designs are emerging in which genetic identifiers are given equal weight to histology. For clinical oncology providers, understanding the potential and the limitations of DNA sequencing will be crucial for providing genomically driven care in this era of precision medicine. |
| publisher |
BioMed Central |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517547/ |
| _version_ |
1613253067269996544 |